Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Macular Edema Secondary to Inflammation: later-stage trial registry
2 of 2 indexed Macular Edema Secondary to Inflammation trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 2 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Macular Edema Secondary to Inflammation: 2 US clinical trials tracked, 2 recruiting.
Macular Edema Secondary to Inflammation is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Kodiak Sciences, running 2 of these trials.
Enrollment posture brief
Registry condition macular-edema-secondary-to-inflammation
OPEN 2 | RECR 100% | LATE 2 | EARLY 0 | RANK #7188 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Macular Edema Secondary to Inflammation lists 2 open slots (100% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Macular Edema Secondary to Inflammation on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Macular Edema Secondary to Inflammation is recruiting above its size-band peers.
2 of 2 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK
Kodiak Sciences
NCT06990399
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE
Kodiak Sciences
NCT06996080
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Macular Edema Secondary to Inflammation records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Macular Edema Secondary to Inflammation trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Macular Edema Secondary to Inflammation page
2 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Macular Edema Secondary to Inflammation trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Kodiak Sciences sponsors the most Macular Edema Secondary to Inflammation trials on record, review their full trial history before evaluating a specific study. See Kodiak Sciences's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Macular Edema Secondary to Inflammation condition card totals 2 registered trials; most-linked intervention KSI-101; top US site state South Carolina. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.